MYCN amplification and ATRX mutations are incompatible in neuroblastoma

Keyphrases

• Activating mutation 33%
• Aggressive Tumor 33%
• All Ages 33%
• ATRX mutation 100%
• Cell Line Models 33%
• Chaperone Complex 33%
• Disease Prognosis 33%
• High-risk Disease 33%
• High-risk Neuroblastoma 33%
• Human Cell Lines 33%
• Improved Outcomes 33%
• Inactivating mutation 33%
• Metabolic Reprogramming 66%
• Mitochondrial Dysfunction 33%
• Mouse Model 33%
• Mutually Exclusive 33%
• MYCN Amplification 100%
• MYCN Oncogene 33%
• Neuroblastoma 100%
• Oncogene 33%
• Oncogene mutation 33%
• Poor Prognosis 33%
• Reactive Oxygen Species Production 33%
• Replicative Stress 66%
• Synthetic Lethality 66%
• Tumor Suppressor Gene 100%

Biochemistry, Genetics and Molecular Biology

• Alpha Thalassemia/Mental Retardation X-Linked 100%
• Mitochondrial Disorder 20%
• Mouse Model 20%
• Oncogene 60%
• Reprogramming 40%
• Synthetic Lethality 40%
• Tumor Suppressor Gene 60%